TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04951713
Drug: XZP-3287 combined with clarithromycin
Normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Drug: XZP-3287, oral, 120 mg once daily for day 1 and day 12 Drug: clarithromycin, oral, 500 mg twice daily for day 8 to day 21
Study: NCT06170983
Drug: Azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 500 mg once daily for 3 days
Study: NCT06155487
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Tablet, Single dose of Placebo 100 mg
Study: NCT06155487
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Tablet, Single dose of Placebo 200 mg
Study: NCT06155487
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Tablet, Single dose of Placebo 300 mg
Study: NCT06155487
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Tablet, Single dose of Placebo 400 mg
Study: NCT06155487
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Tablet,Single dose of Placebo 600 mg
Study: NCT06155487
Drug: AJH-2947 200 mg (MAD)
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral Tablet, Multiple (once daily for 7days) oral dose of AJH-2947 200 mg
Study: NCT05681845
Drug: NNC0365-3769 (Mim8)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive a single dose of Mim8 subcutaneously in the abdomen.
Study: NCT05742841
Drug: moderate- or high-intensity statin/ rosuvastatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: moderate- or high-intensity statin (either rosuvastatin 10mg daily or rosuvastatin 40 mg daily)
Study: NCT05547503
Drug: AFA-281
Normalized name: ADAPTER,ASPIRA/FLUSH,LUER URESIL AFA-LL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Part 1: AFA-281 will be administered as a single dose at 4 dose levels (TBD) Part 2: AFA-281 will be administered twice daily for 14 - 21 days at 3 dose levels (TBD)
Study: NCT04836507
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered according to package insert
Study: NCT05227768
Drug: VV116 25mg Group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 subjects will receive VV116 25mg,orally; 2 subjects will receive placebo,orally.
Study: NCT05227768
Drug: VV116 200mg Group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 subjects will receive VV116 200mg,orally; 2 subjects will receive placebo,orally.
Study: NCT05227768
Drug: VV116 400mg Group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 subjects will receive VV116 400mg,orally; 2 subjects will receive placebo,orally.
Study: NCT05227768
Drug: VV116 800mg Group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 subjects will receive VV116 800mg,orally; 2 subjects will receive placebo,orally.
Study: NCT05227768
Drug: VV116 1200mg Group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 subjects will receive VV116 1200mg,orally; 2 subjects will receive placebo,orally.
Study: NCT05107921
Drug: Bromfenac Sodium
Normalized name: Bromfenac Sodium
DrugBank: Bromfenac (DB00963)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The study participants will receive bromfenac sodium hydrate eyedrops twice daily for 14 days.
Study: NCT04958434
Drug: TST005
Approvals — FDA: no, EMA: no, PMDA: no
Description: TST005 is a bifunctional human immunoglobulin G1 (IgG1) monoclonal
Study: NCT06548490
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be a dry needle stick; no substances will be injected
Study: NCT05906056
Drug: Zoledronic Acid Injection
Normalized name: zoledronic acid Injection
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: one dose of intravenous zoledronic acid will be administered
Study: NCT04118556
Drug: Best available Treatment (BAT)
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: The BAT in this study will freely be identified by the Investigator prior to patient randomization and may include treatments such as: extracorporeal photopheresis (ECP), low-dose methotrexate (MTX), mycophenolate mofetil (MMF), mTOR inhibitors (everolimus or sirolimus), etanercept, vedolizumab, ruxolitinib or infliximab. Dose and frequency will depend on label (where approved) and institutional guidelines for various BAT.
Study: NCT05717764
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine will be administered orally in a 3-week treatment cycle, twice a day from day 1 to day 14 of each cycle.
Study: NCT06351917
Drug: PlexoZome® Levagen® topical spray solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: PlexoZome® Levagen® topical spray solution 10mg/g providing 1.8mg active per pump
Study: NCT06351917
Drug: Placebo topical spray solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo topical spray solution topical spray solution 0mg/g providing 0mg active per pump
Study: NCT05319756
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive a single oral dose of a placebo that looks like gabapentin and a placebo that looks like oxycodone HCl
Study: NCT03636958
Drug: conventional antiepileptic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: choice of the molecule is left to the discretion of the clinician excluding the following benzodiazepines: clobazam, clonazepam, diazepam. Antiepileptic drugs allowed are therefore: lamotrigine, levetiracetam, lacosamide, sodium valproate, carbamazepine, oxcarbabazepine, slicarbazepine, pregabalin, gabapentin, topiramate, phenytoin, phenobarbital, zonisamide, vigabatrin.
Study: NCT00378456
Drug: Antioxidants- (Vitamins A,C,E Selenium and Zinc)
Normalized name: antioxidant 119
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05724485
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12.45 grams of Maltodextrin orally per day before bedtime
Study: NCT05452005
Drug: [18F]-αvβ6-BP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will be injected twice with up to 10 millicurie (mCi) of 18F-αvβ6-BP as a rapid intravenous (i.v) bolus.
Study: NCT06051721
Drug: CYB004
Approvals — FDA: no, EMA: no, PMDA: no
Description: CYB004 is a synthetic deuterated N, N-Dimethyltryptamine (DMT) analog.
Study: NCT05413811
Drug: 5 Fluorouracil (5 FU) Cream
Normalized name: fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravaginal topical chemotherapy, 5-fluorouracil cream
Study: NCT05413811
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravaginal topical placebo cream
Study: NCT05750017
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mL per dose, containing 4.5 mg sodium chloride.
Study: NCT05512910
Drug: Minocycline
Normalized name: Minocycline
DrugBank: Minocycline (DB01017)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 200 mg minocycline orally or via nasogastric tube prior to successful reperfusion, followed by 100 mg every 12 hours times for a total of 5 days. If vomiting occurs within half an hour of the first dose, the clinician should assess the necessary of re-administering 100mg based on the severity of vomiting.
Study: NCT04879823
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen will be prescribed at 10 mg/kg to be taken every 6 hours for the first three post-operative days. After the first three days, the subject should take the ibuprofen every 6 hours as needed for pain control. The daily dose of ibuprofen is not to exceed 1200mg or more than 4 individual doses. It will be prescribed in liquid suspension form for ease of use in pediatric populations. Subjects or parents will purchase this medication and dosage will be given to subjects in easy-to-understand language.
Study: NCT04879823
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen will be prescribed at 15mg/kg to be taken every 4 hours for the first three days, except when sleeping. After the first three days, the subject should take the acetaminophen every 4 hours as needed for pain control. The daily dose of acetaminophen is not to exceed 5 doses in 24 hours. It will be prescribed in liquid suspension form for ease of use in pediatric populations. Subjects or parents will purchase this medication and dosage will be given to subjects in easy-to-understand language.
Study: NCT04879823
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: An equal volume of water will be prescribed to patients (0.5mg/kg) with a max dose of 20mg to be taken the morning of days 2, 4, and 6 post-operatively. The placebo (water) will be mixed by the parents with 5mL of pre-packaged cherry syrup.
Study: NCT05548647
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: An inactive saline solution administered via subcutaneous injection
Study: NCT06488105
Drug: Statin (rosuvastatin 10 or 40 mg daily, depending on risk)
Normalized name: rosuvastatin 40 MG
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: moderate- or high-intensity statin (either rosuvastatin 10 mg daily or rosuvastatin 40 mg daily)
Study: NCT05243602
Drug: Switch to B/F/TAF
Approvals — FDA: no, EMA: no, PMDA: no
Description: This is a combined pill containing 50mg of bictegravir, 200mg of emtricitabine and 25mg of tenofovir alafenamide
Study: NCT05243602
Drug: Continue current regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will continue taking the same ARV regimen they were on before enrollment with no change in drug or dosage for the duration of the trial
Study: NCT06516562
Drug: Optimal treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimal treatment using current National Guidelines for the diagnosis and treatment of chronic heart failure
Study: NCT05813249
Drug: Rybelsus Oral Product
Normalized name: Rybelsus Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Semaglutide
Study: NCT05813249
Drug: Ozempic Injectable Product
Normalized name: Ozempic Injectable Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous Semaglutide
Study: NCT05045638
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral dose
Study: NCT05584761
Drug: unrelated umbilical cord blood
Normalized name: Bos taurus umbilical cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single unit of unrelated umbilical cord blood was reinfused within 24-72 hours after the end of AZA or chemotherapy, and the longest delay was 96 hours after the end of chemotherapy. The umbilical cord blood was matched at 0-3/10 locus.~Microtransplantation of umbilical cord blood: single unit of unrelated cord blood (HLA 0-5/10 or 0-3/6 matched, TNC 1-2×107/Kg body weight), AZA or homoharringtonine infusion 24-72 hours after the end of injection.
Study: NCT05977699
Drug: salbutamol aqueous solution
Normalized name: ethylcellulose aqueous dispersion type A
Approvals — FDA: no, EMA: no, PMDA: no
Description: administration of 200microliters of salbutamol to reverse methacholine induced bronchoconstriction using a vibrating mesh nebulizer
Study: NCT05563961
Drug: Panadol®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference Drug. Multiple-dose stage: Cohort 1, 2 tablets Q6H (total 4 dosages, 8 tablets or 4,000 mg)
Study: NCT05563961
Drug: SafeTynadol®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test Drugs. Multiple-dose stage:~Cohort 2, 2 tablets Q6H (total 4 dosages, 8 tablets or 4,000 mg) Cohort 3, 3 tablets at first dosage and 2 tablets at second to forth dosage Q6H (total 4 dosages, 9 tablets or 4,500 mg) Cohort 4, 3 tablets at first to second dosage and 2 tablets at third to forth dosage Q6H (total 4 dosages, 10 tablets or 5,000 mg) Cohort 5, 3 tablets Q6H (total 4 dosages, 12 tablets or 6,000 mg) Cohort 6, 4 tablets Q6H (total 4 dosages, 16 tablets or 8,000 mg) Cohort 7, 5 tablets Q6H (total 4 dosages, 20 tablets or 10,000 mg) Cohort 8, 6 tablets Q6H (total 4 dosages, 24 tablets or 12,000 mg)
Study: NCT06383507
Drug: CHT101
Approvals — FDA: no, EMA: no, PMDA: no
Description: After lymphodepletion with Fludarabine and Cyclophosphamide, CD70 UCAR T cells were transfused intravenously.
Study: NCT05832489
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will have 2 imaging sessions (MRI and EEG) after either:~* methylphenidate immediate release 25 mg~* placebo~in a cross-over design. The two imaging sessions will be separated by 11 to 87 days.
Study: NCT05602961
Drug: BNT162b2/COMIRNATY®
Approvals — FDA: no, EMA: no, PMDA: no
Description: active control
Study: NCT06645522
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo injection every 12 hours for 7 days; sequentially a sublingual dose of placebo drug twice a day for 21 days.
Study: NCT06355856
Drug: DNN.22.17.036
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apply twice daily to the affected area and around it.
Study: NCT04790370
Drug: Anticoagulation with heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-molecular weight heparin (LMWH) or unfractionated heparin (UFH)
Study: NCT06025630
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo pills containing microcrystalline cellulose will be ingested over the course of the 8 week intervention.
Study: NCT05425355
Drug: Intravenous (IV) placebo plus oral acetaminophen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperatively patients will receive both a tablet and an IV solution every 6 hours for 48 hours, for a total of 8 doses. In this group the IV study drug will be normal saline and the pill will be acetaminophen
Study: NCT04764383
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Microcrystalline cellulose (placebo) 1000 mg capsules taken by mouth (PO) twice daily (BID).
Study: NCT06083844
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given by mouth
Study: NCT06168994
Drug: Eplerenone
Normalized name: Eplerenone
DrugBank: Eplerenone (DB00700)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amiodarone vs eplerenone in AF
Study: NCT05359783
Drug: Superparamagnetic Iron Oxide
Normalized name: Superparamagnetic iron oxide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Superparamagnetic iron oxide (SPIO) consists of an iron oxide nanoparticle core and a hydrophilic coating to make it biocompatible and colloidal stable in a suspension.
Study: NCT05610891
Drug: CLR 131
Approvals — FDA: no, EMA: no, PMDA: no
Description: CLR 131 will be administered IV (intravenously) at a dose based on patients' BSA
Study: NCT06014957
Drug: spinal anesthesia
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12.5 mg of 0.5% hyperbaric levobupivacaine (2.5 ml) was given at the level of L4-5 interspaces after the free flow confirming of the cerebrospinal fluid (CSF), immediately positioned supine with one pillow supporting the head and shoulders
Study: NCT06277245
Drug: LNK01001
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule; Oral
Study: NCT06277245
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule; Oral
Study: NCT05048589
Drug: Standard-Dose Quadrivalent Influenza Vaccine
Normalized name: influenza A virus (H1N1) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: For the control arm, the standard-dose quadrivalent influenza vaccines Influvactetra® and Vaxigriptetra will be used.
Study: NCT05048589
Drug: High-Dose Quadrivalent Influenza Vaccine
Normalized name: influenza A virus (H1N1) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: For the control arm, the high-dose quadrivalent influenza vaccine Efluelda®/Fluzone® High-Dose Quadrivalent will be used.
Study: NCT06014957
Drug: saddle block
Normalized name: Saddle Block-22
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12.5 mg of 0.5% hyperbaric levobupivacaine (2.5 ml) was given at the level of L4-5 interspaces after the free flow confirming of the cerebrospinal fluid (CSF), placed in the sitting position for ten minutes and then supine with one pillow supporting the head and shoulders
Study: NCT05676476
Drug: Antihypertensive treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antihypertensive treatment to goal of less than 140/90 mmHg
Study: NCT05769920
Drug: TTHX1114(NM141) Ophthalmic Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eye drop twice daily
Study: NCT06585644
Drug: Furmonertinib in combination with Anrotinib and chemotherapy
Normalized name: picodralazine and diuretics, combinations with psycholeptics
Approvals — FDA: no, EMA: no, PMDA: no
Description: The enrolled patients are planned to receive preoperative treatment with a combination of furmonertinib and anrotinib, along with platinum-based doublet chemotherapy. Three weeks after the completion of this treatment, they will undergo curative lung lobe resection and systemic lymph node dissection. Postoperatively, they will continue taking furmonertinib for one year. In case of disease progression, they will be switched to comprehensive therapy.
Study: NCT05952713
Drug: Antidepressant
Normalized name: Antidepressant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment with an antidepressant according to Danish register data.
Study: NCT05313802
Drug: LY3502970
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally.
Study: NCT05775718
Drug: Zoster Vaccine Recombinant
Normalized name: zoster vaccine recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection
Study: NCT06716970
Drug: QR12000 75mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: QR12000 75mg QD
Study: NCT06716970
Drug: QR12000 75mg placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo of QR12000 75mg QD
Study: NCT06716970
Drug: QR12000 150mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: QR12000 150mg QD
Study: NCT06716970
Drug: QR12000 150mg placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo of QR12000 150mg QD
Study: NCT05831995
Drug: ABM-168
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dosage: 0.5 mg; 2 mg; 6 mg; once daily by oral administration
Study: NCT05266963
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT04921384
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% normal saline, intravenously
Study: NCT06204120
Drug: LPM3480392 Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCA administration
Study: NCT06204120
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCA administration
Study: NCT05066230
Drug: KSI-301
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal injection
Study: NCT06512116
Drug: SIBP-A17
Approvals — FDA: no, EMA: no, PMDA: no
Description: Strength: 1, 2, 4, 5, 6 or 8 mg. Intravenous infusion administration, with a treatment cycle of every 21 days, administered once on the first day of each cycle.~The dose escalation stage, 1mg/kg and 2mg/kg were subjected to accelerated titration, where the safety was evaluated within 21 days after the first administration to one subject. If dose-limiting toxicity (DLT) occurred, the traditional 3+3 dose escalation method was immediately switched. If DLT does not occur, the next dose group will be explored, and the dose exploration starting from 4mg/kg will adopt a 3+3 dose escalation design.
Study: NCT05610254
Drug: Ringer's Lactate
Normalized name: Ringer's lactate/gel dressing 2.2" TOPICAL KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: On the first trial day healthy volunteers are randomized to receive 30 ml/kg of Ringer's lactate either cold (15°C, 59°F), or at body temperature (37°C, 98.6°F) during a 30-minute interval. After a minimum washout period of 24 hours, subjects are switched to receive infusion at the other aforementioned temperatures.
Study: NCT06030258
Drug: IN10018
Approvals — FDA: no, EMA: no, PMDA: no
Description: orally taken once daily
Study: NCT04618575
Drug: Ursodeoxycholic acid combined with total glucosides of paeony
Normalized name: ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ursodeoxycholic acid combined with total glucosides of paeony
Study: NCT04618575
Drug: Ursodeoxycholic acid only
Normalized name: Ursodeoxycholic acid only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ursodeoxycholic acid only
Study: NCT00367419
Drug: Erythromycin
Normalized name: Erythromycin
DrugBank: Erythromycin (DB00199)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT05288023
Drug: Azithromycin for Oral Suspension
Normalized name: Azithromycin for Oral Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin will be administered as a single dose in oral suspension form for children (up to the maximum adult dose of 1g).~Dosage will be calculated by age for children aged 1-5 months. For children 6-59 months of age, height-based dosing will be used via height-stick approximation as currently performed by Niger's trachoma program.
Study: NCT06083480
Drug: GlyNAC (combination of glycine and n-acetylcysteine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GlyNAC 200 mg/kg/day (100mg glycine and 100mg N-acetyl-cysteine) will be administered orally in two divided doses each day for four weeks prior to TKA and six weeks postoperatively. The preparation will be a commercially available product of 1:1 ratio of glycine and N-acetyl-cysteine.
Study: NCT06083480
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (alanine) 200 mg/kg/day will be administered orally in two divided doses each day for four weeks prior to TKA and six weeks postoperatively.
Study: NCT05442580
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Lymphodepleting chemotherapy administered at physician discretion
Study: NCT05273775
Drug: HRS5091 Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: HRS5091 Tablets once daily
Study: NCT05273775
Drug: Rosuvastatin Calcium Tablets
Normalized name: Rosuvastatin Calcium
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Rosuvastatin Calcium Tablets single dose
Study: NCT05219799
Drug: Norepinephrine
Normalized name: Norepinephrine
DrugBank: Norepinephrine (DB00368)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Regional forearm infusion at 8 ng/dL/min via brachial artery catheter during normoxia and hypoxia exposures
Study: NCT06006559
Drug: EYU688
Approvals — FDA: no, EMA: no, PMDA: no
Description: EYU688 administered by oral route
Study: NCT06006559
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo administered orally as capsules